SBIR Phase I: Bioresorbable Polyurethane Scaffold Materials for Regenerative Applications in Advanced Wound Healing

这个小企业创新研究（SBIR）第一阶段项目旨在开发一种生物可吸收支架材料，用于高级伤口愈合，即，糖尿病溃疡和褥疮。具体目标是开发一种高度多孔的生物材料，其是双功能的，即，用作真空治疗（负压伤口治疗-NPWT）伤口的敷料材料，也可用作组织再生的支架。研究表明，由于组织长入当前敷料，接受NPWT治疗的患者必须经历多次疼痛的敷料更换。此外，在敷料更换期间的这种重复损伤进一步延迟愈合。该项目将通过开发一种可吸收敷料-支架材料来解决这一重要的未满足需求，该材料将允许在NPWT期间向内生长，然后以期望的速率降解，以允许伤口内的正常组织再生和组织化。该技术解决了高级伤口愈合的主要临床未满足的需求，并将显著降低治疗成本，同时改善患有这些使人衰弱的伤口的患者的生活质量。该研究的更广泛影响是在普通，心胸和整形外科的组织再生和修复中的各种应用;创伤，运动医学和骨折愈合。这种新型支架技术将在使用工业发泡和热网状技术的大规模泡沫制造方法的框架内开发。这也将降低生物材料的成本，并大大影响美国广泛临床应用领域的医疗保健支出。

This Small Business Innovation Research (SBIR) Phase I project aims to develop a bioresorbable scaffold material for applications in advanced wound healing, i.e., diabetic ulcers and pressure sores. The specific goal is to develop a highly porous biomaterial that is bifunctional, i.e., used as a dressing material for wounds treated with vacuum therapy (Negative Pressure Wound Therapy-NPWT), and also serve as a scaffold for tissue regeneration. Research shows that patients treated with NPWT have to undergo several painful dressing changes due to the tissue ingrowth that occurs into current dressings. Further, this repeated injury during dressing changes further delays healing. The project will address this important unmet need by developing a resorbable dressing-scaffold material that will allow ingrowth during NPWT, and then degrade at a desired rate to allow normal tissue to be regenerated and organized within the wounds. The technology addresses major clinical unmet needs in advanced wound healing and will produce significant reductions in treatment costs while improving the quality of life for patients who suffer from these debilitating wounds.The broader impacts of this research are in a variety of applications in tissue regeneration and repair for general, cardiothoracic, and plastic surgery; trauma, sportsmedicine, and fracture healing. This novel scaffold technology will be developed within the framework of large scale foam manufacturing methods using industrial foaming and thermal reticulation techniques. This will also reduce the cost of the biomaterial and substantially impact healthcare spending across a broad range of clinical application areas in the US.